Therapeutics Company Announces Promising Preclinical Data For Advanced Cancer Treatment

Monopar Therapeutics Announces Significant Preclinical Data for MNPR-101 Radiopharma Program Targeting Advanced Cancers.

Disclaimer: This article contains affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Monopar Therapeutics Inc., an innovative clinical-stage biopharmaceutical company, recently announced promising preclinical data for its MNPR-101 Radiopharma Program. The program is specifically designed to…